This study sought to correlate sacubitril/valsartan versus enalapril in patients with heart failure with reduced ejection fraction (HFrEF) based on peak oxygen consumption (VO2) and 6-minute walk test (6-MWT). Researchers enrolled 52 participants with HFrEF with a left ventricular ejection fraction < 40% to receive either sacubitril/valsartan (target dose of 400 mg daily) or enalapril (target dose of 40 mg daily). Via using cardiopulmonary exercise testing, peak VO2 was assessed. They also conducted a six-minute walk test. As per the findings, sacubitril/valsartan did not substantially improve peak VO2 or 6-MWT after 12 or 24 weeks in participants with HFrEF compared with enalapril.
Read the full article on American Heart Journal.